Dermatology Times' Sunday Crossword: May 18, 2025

Welcome to Dermatology Times' Sunday Crossword, where dermatology knowledge meets fun! Each week, we curate a selection of words and terms pulled directly from the latest news in the dermatology world. Whether it's breakthrough treatments, new research findings, or emerging trends, this crossword serves as both a challenge and an opportunity to reinforce your expertise in the field.

This week, we're focusing on 2 recent Dermatology Times DermView custom video series, spotlighting insights from Lisa Swanson, MD, and Lawrence Eichenfield, MD, in "Updates in Pediatric Atopic Dermatitis," and Susan Taylor, MD, FAAD, "Sun Shield: Protecting Beyond Ultraviolet Light." View all episodes of the video series with the above links for additional insights.

Try out either our interactive crossword or a static/non-interactive version below.

Interactive Crossword

This crossword was created with CrosswordLabs.com.

Static/Non-Interactive Crossword

Across

1. Topical phosphodiesterase-4 inhibitor used for AD

5. Antioxidant known to support skin barrier and reduce inflammation

6. Antioxidant compounds found in plants, sometimes added to skin care

11. IL-13 inhibitor used systemically for pediatric AD

13. Molecules like vitamin C and E used to neutralize free radicals

Down

2. Nonsteroidal topical agent for pediatric AD

3. Immune pathway heavily involved in pediatric AD

4. Asthma or allergic rhinitis in children with AD

6. Type of burden discussed in relation to pediatric AD

7. Topical JAK inhibitor used in pediatric AD

8. Chemical sunscreen ingredient that absorbs UV radiation

9. Form of solar radiation contributing to oxidative skin damage

10. Oxidative ___ damages skin cells and accelerates aging

12. Common symptom driving the scratch cycle in atopic dermatitis

For answers to this week's puzzle, check out next week's edition of the Dermatology Times Sunday Crossword.

Answers from our May 11, 2025 puzzle: [Across: 3 - GLP1; 6 - melanoma; 7 - FDA; 9 - trust; 11 - OX40; 12 - delgocitinib; 13 - NewBeauty; 14 - ixekizumab; Down: 1 - soquelitinib; 2 - upadacitinib; 4 - nonadherence; 5 - roflumilast; 8 - abrocitinib; 10 - SOCS]